Abstract:Early diagnosis and therapy are crucial to control disease progression optimally and achieve a good prognosis in rheumatoid arthritis (RA). Previous study showed that a technetium-99m (99mTc)-labeled TSPO ligand (99mTc-CB256 [2-(8-(2-(bis(pyridin-2-yl)methyl)amino)acetamido)-2-(4-chlorophenyl)H-imidazo[1,2-a]pyridin-3-yl)-N,N-dipropylacetamide] composed of a translocator protein (TSPO) ligand CB86 [[2-(4-chlorophenyl)-8-amino-imidazo[1,2-a]-pyridin-3-yl]-N,N-di-n-propylacetamide] and di-(2-picolyl)amine, a bifunctional chelate agent, was used to image a TSPO-rich cancer cell in vitro; however, few 99mTc-CB256 in vivo evaluation has been reported so far probably due to the cytotoxicity of CB256 (ca. 75 times more than analogous CB86). Herein, we describe a novel TSPO targeting radiopharmaceutical consisting of CB86 and diethylenetriaminepentaacetic acid (DTPA), a conventional bifunctional chelating ligand in clinical trials used to prepare 99mTc-labeled CB86, and its evaluation as a 99mTc-single-photon emission computed tomography (SPECT) probe. The radiosynthesis and characterization of 99mTc-DPTA-CB86 including hydrophilicity and stability tests were determined. Additionally, the binding affinity and specificity of 99mTc-DTPA-CB86 to TSPO were evaluated using RAW264.7 macrophage cells. Biodistribution and 99mTc-SPECT studies were conducted on rheumatoid arthritis (RA) rat models after the injection of 99mTc-DTPA-CB86 with or without co-injection of unlabeled DTPA-CB86. The radiosynthesis of 99mTc-DTPA-CB86 was completed successfully with the labeling yields and radiochemical purity of 95.86 ± 2.45 and 97.45 ± 0.69%, respectively. The probe displayed good stability in vitro and binding specificity to RAW264.7 macrophage cells. In the biodistribution studies, 99mTc-DTPA-CB86 exhibited rapid inflammatory ankle accumulation. At 180 min after administration, 99mTc-DTPA-CB86 uptakes of the left inflammatory ankle were 2.35 ± 0.10 percentage of the injected radioactivity per gram of tissue (% ID/g), significantly higher than those of the normal tissues. 99mTc-SPECT imaging studies revealed that 99mTc-DTPA-CB86 could clearly identify the left inflammatory ankle with good contrast at 30–180 min after injection. Therefore, 99mTc-DTPA-CB86 may be a promising probe for arthritis 99mTc-SPECT imaging.This article has not yet been cited by other publications.

Development of superior bone scintigraphic agent from a series of (99m)Tc-labeled zoledronic acid derivatives

Preparation, biological characterization and preliminary human imaging studies of 68Ga-DOTA-IBA

Synthesis and Evaluation of a Novel 99mtc Nitrido Radiopharmaceutical with Alendronate Dithiocarbamate As a Potential Bone‐imaging Agent

Development of a 99mTc-labeled tetrazine for pretargeted SPECT imaging using an alendronic acid-based bone targeting model

Study of Biodistribution Properties of a New Myocardial Imaging Agent 99Tcm-N-DBODC5

Synthesis and Evaluation Of111in-Dota-mab109 Monoclonal Antibody for Potential SPECT Molecular Imaging

Safety and Efficacy of 68Ga- or 177Lu-Labeled DOTA-IBA as a Novel Theranostic Radiopharmaceutical for Bone Metastases

Theranostic Agent Targeting Bone Metastasis: A Novel [ 68 Ga]Ga/[ 177 Lu]Lu-DOTA-HBED-bisphosphonate

Preparation and experimental study of a new renal imaging agent: N, N-BIS (2-aminoethyl) propane haxaacetic acid labeled with technitium-99m

Synthesis and evaluation of 111 In-labeled d -glucose as a potential SPECT imaging agent

Synthesis, Biodistribution and Quantitative Structure-Activity Relationship Studies of New 99mtc Labeled Pseudo-Peptide Complexes.

Synthesis of Labelled Small Peptide Complexes for Imaging Agents with Technetium-99M and Biodistribution in Mice.

Preparation of New Technetium-99m Nns/X Complexes and Selection for Brain Imaging Agent

Preclinical Evaluation of a Novel 99m Tc-Labeled CB86 for Rheumatoid Arthritis Imaging

Development of [ 64 Cu]Cu-BPAMD for PET imaging of bone metastases

Preclinical Evaluation of a Novel 99Mtc-Labeled CB86 for Rheumatoid Arthritis Imaging.

Design and evaluation of 32P-labeled hydroxyapatite nanoparticles for bone tumor therapy

Quasi-dendritic sulfonate-based organic small molecule for high-quality NIR-II bone-targeted imaging

Preparation and Biological Evaluation of 111In-Triphenylphosphonium Cations

Study on pharmacokinetics and acute toxicity of new molecular probe 99 m Tc-RRL

Development of 99tcm Labelled Mixed-ligand Complexes